Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized Neoantigen DC Immunotherapy in Advanced Solid Tumors
NCT05767684Phase 1Recruiting
- Sponsor
- National Health Research Institutes
- Start
- Jun 2023
- Primary completion
- Mar 2025
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of Neo-DCVac in pancreatic cancer (PC), liver cancer, biliary tract cancer (BTC) and 1 more (2 arms), sponsored by National Health Research Institutes. Primary endpoint: Number of subjects experienced limiting toxicities at 6 weeks. Started Jun 2023; status: recruiting.
02
Drugs
Neo-DCVac
03
Conditions
pancreatic cancer (PC)liver cancerbiliary tract cancer (BTC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05767684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05767684.